Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study

Liang-Yu Lin, Chin-Chou Huang, Jia-Shiong Chen, Tao-Cheng Wu, Hsin-Bang Leu, Po-Hsun Huang, Ting-Ting Chang, Shing-Jong Lin, Jaw-Wen Chen, Liang-Yu Lin, Chin-Chou Huang, Jia-Shiong Chen, Tao-Cheng Wu, Hsin-Bang Leu, Po-Hsun Huang, Ting-Ting Chang, Shing-Jong Lin, Jaw-Wen Chen

Abstract

Background: Circulating endothelial progenitor cells (EPCs) reflect endothelial repair capacity and may be a significant marker for the clinical outcomes of cardiovascular disease. While some high-dose statin treatments may improve endothelial function, it is not known whether different statins may have similar effects on EPCs.This study aimed to investigate the potential class effects of different statin treatment including pitavastatin and atorvastatin on circulating EPCs in clinical setting.

Methods: A pilot prospective, double-blind, randomized study was conducted to evaluate the ordinary dose of pitavastatin (2 mg daily) or atorvastatin (10 mg daily) treatment for 12 weeks on circulating EPCs in patients with cardiovascular risk such as hypercholesterolemia and type 2 diabetes mellitus (T2DM). Additional in vitro study was conducted to clarify the direct effects of both statins on EPCs from the patients.

Results: A total of 26 patients (19 with T2DM) completed the study. While the lipid-lowering effects were similar in both treatments, the counts of circulating CD34+KDR+EPCs were significantly increased (from 0.021 ± 0.015 to 0.054 ± 0.044% of gated mononuclear cells, P < 0.05) only by pitavastatin treatment. Besides, plasma asymmetric dimethylarginine level was reduced (from 0.68 ± 0.10 to 0.53 ± 0.12 μmol/L, P < 0.05) by atorvastatin, and plasma vascular endothelial growth factor (VEGF) level was increased (from 74.33 ± 32.26 to 98.65 ± 46.64 pg/mL, P < 0.05) by pitavastatin. In the in vitro study, while both statins increased endothelial nitric oxide synthase (eNOS) expression, only pitavastatin increased the phosphorylation of eNOS in EPCs. Pitavastatin but not atorvastatin ameliorated the adhesion ability of early EPCs and the migration and tube formation capacities of late EPCs.

Conclusions: While both statins similarly reduced plasma lipids, only pitavastatin increased plasma VEGF level and circulating EPCs in high-risk patients, which is probably related to the differential pleiotropic effects of different statins.

Trial registration: This trial is registered at ClinicalTrials.gov, NCT01386853.

Figures

Figure 1
Figure 1
Representative flow cytometry analysis for quantifying the number of circulating endothelial progenitor cells (EPCs).
Figure 2
Figure 2
Percentage of stained dual-positive endothelial progenitor cells (EPCs) of gated mononuclear cells analyzed by flow cytometry. There are no differences of (A) CD34+CD133+ EPCs and (B) CD133+KDR+ EPCs between pitavastatin and atorvastatin groups. (C) The levels of circulating CD34+KDR+ EPCs are significantly increased after 12 week treatment with pitavastatin. *: p < 0.05 compared with baseline.
Figure 3
Figure 3
Pitavastatin significantly increased the adhesion function of early endothelial progenitor cells (EPCs). Early EPCs were pretreated with pitavastatin and atorvastatin (10−7 M) for 24 hours. The number of adhesion of early EPC was analyzed by fibronectin-adhesion assay (n = 12) (A). The effects of pitavastatin and atorvastatin on the proliferation of late EPCs, analyzed by MTT assay after treatment with different doses of statins for 24 hours (B), migration (C) and capillary tube formation (D). Data are presented as mean ± SD in each experiment; n = 4. *: p < 0.05 compared with control.
Figure 4
Figure 4
Pitavastatin increased the endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) expression in human endothelial progenitor cells (EPCs). Late EPCs were pretreated with pitavastatin and atorvastatin (10−7 M) for 24 hours. Both of pitavastatin and atorvastatin increased significantly total form of eNOS activation analyzed by Western blotting (A). Ratio of phosphorylated eNOS over total eNOS significantly increased only in late EPCs after co-incubated with pitavasatin (B). Pitavastatin (10−7 M) increased significantly expression of VEGF in early EPCs analyzed by Western blotting (C). *: P < 0.05 was considered significant.
Figure 5
Figure 5
Schematic representation of the possible mechanism of effects of pitavastatin and atorvastatin on endothelial progenitor cells (EPCs). Atorvastatin decreased serum asymmetric dimethylarginine (ADMA) and pitavastatin increased serum vascular endothelial growth factor (VEGF), both increasing the expression of total form endothelial nitric oxide synthase (eNOS) in late EPCs. Only pitavastatin could increase circulating EPCs number and function via enhancing eNOS activity.

References

    1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ. et al.American heart association statistics committee and stroke statistics subcommittee: heart disease and stroke statistics–2012 update: a report from the American heart association. Circulation. 2012;125:e2–e220. doi: 10.1161/CIR.0b013e31823ac046.
    1. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C. TNT steering committee members and investigators: treating to new targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004;93:154–158. doi: 10.1016/j.amjcard.2003.09.031.
    1. Liu Y, Wei J, Hu S, Hu L. Beneficial effects of statins on endothelial progenitor cells. Am J Med Sci. 2012;344:220–226. doi: 10.1097/MAJ.0b013e31824998f9.
    1. Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull. 2003;26:1681–1684. doi: 10.1248/bpb.26.1681.
    1. Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi S, Takeuchi M, Hiro T, Kimura T, Nakagawa Y, Yamagishi M, Ozaki Y, Matsuzaki M. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol. 2013;12:5. doi: 10.1186/1475-2840-12-5.
    1. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3 T3-L1 adipocytes. FEBS Lett. 2001;507:357–361. doi: 10.1016/S0014-5793(01)03007-1.
    1. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005;59:239–252. doi: 10.1111/j.1742-1241.2005.00461.x.
    1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–967. doi: 10.1126/science.275.5302.964.
    1. Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol. 2007;49:741–752. doi: 10.1016/j.jacc.2006.09.050.
    1. Michaud SE, Dussault S, Haddad P, Groleau J, Rivard A. Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities. Atherosclerosis. 2006;187:423–432. doi: 10.1016/j.atherosclerosis.2005.10.009.
    1. Tobler K, Freudenthaler A, Baumgartner-Parzer SM, Wolzt M, Ludvik B, Nansalmaa E, Nowotny PJ, Seidinger D, Steiner S, Luger A, Artwohl M. Reduction of both number and proliferative activity of human endothelial progenitor cells in obesity. Int J Obes. 2010;34:687–700. doi: 10.1038/ijo.2009.280.
    1. Hibbert B, Ma X, Pourdjabbar A, Simard T, Rayner K, Sun J, Chen YX, Filion L, O’Brien ER. Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries. PLoS One. 2011;6:e16413. doi: 10.1371/journal.pone.0016413.
    1. Baran Ç, Durdu S, Dalva K, Zaim Ç, Dogan A, Ocakoglu G, Gürman G, Arslan Ö, Akar AR. Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial. Stem Cell Rev. 2012;8:963–971. doi: 10.1007/s12015-011-9321-z.
    1. Schmidt-Lucke C, Fichtlscherer S, Rössig L, Kämper U, Dimmeler S. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis. 2010;211:249–254. doi: 10.1016/j.atherosclerosis.2010.02.007.
    1. Tousoulis D, Andreou I, Tsiatas M, Miliou A, Tentolouris C, Siasos G, Papageorgiou N, Papadimitriou CA, Dimopoulos MA, Stefanadis C. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214:151–157. doi: 10.1016/j.atherosclerosis.2010.11.002.
    1. Paradisi G, Bracaglia M, Basile F, Di’Ipolito S, Di Nicuolo F, Ianniello F, Quagliozzi L, Donati L, Labianca A, Di Cesare C, Viggiano M, Biaggi A, De Waure C, Andreotti F, Di Simone N, Caruso A. Effect of pravastatin on endothelial function and endothelial progenitor cells in healthy postmenopausal women. Clin Exp Obstet Gynecol. 2012;39:153–159.
    1. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, März W, Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111:2356–2363. doi: 10.1161/01.CIR.0000164260.82417.3F.
    1. Huang PH, Chen YH, Tsai HY, Chen JS, Wu TC, Lin FY, Sata M, Chen JW, Lin SJ. Intake of red wine increases the number and functional capacity of circulating endothelial progenitor cells by enhancing nitric oxide bioavailability. Arterioscler Thromb Vasc Biol. 2010;30:869–877. doi: 10.1161/ATVBAHA.109.200618.
    1. Chen YH, Lin SJ, Lin FY, Wu TC, Tsao CR, Huang PH, Liu PL, Chen YL, Chen JW. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes. 2007;56:1559–1568. doi: 10.2337/db06-1103.
    1. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow–derived endothelial progenitor cells. J Clin Invest. 2001;108:399–405. doi: 10.1172/JCI200113131.
    1. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D, Mueller M, Fuchs M, Hornig B, Haller H, Drexler H. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004;110:1933–1939. doi: 10.1161/01.CIR.0000143232.67642.7A.
    1. Shao H, Tan Y, Eton D, Yang Z, Uberti MG, Li S, Schulick A, Yu H. Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells. 2008;26:1376–1384. doi: 10.1634/stemcells.2007-0785.
    1. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Inner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964–3972. doi: 10.1093/emboj/18.14.3964.
    1. Sobrino T, Blanco M, Pérez-Mato M, Rodríguez-Yáñez M, Castillo J. Increased levels of circulating endothelial progenitor cells in patients with ischaemic stroke treated with statins during acute phase. Eur J Neurol. 2012;19(12):1539–46. doi: 10.1111/j.1468-1331.2012.03770.x.
    1. Steinmetz M, Pelster B, Lucanus E, Arnal JF, Nickenig G, Werner N. Atorvastatin-induced increase in progenitor cell levels is rather caused by enhanced receptor activator of NF-kappaB ligand (RANKL) cell proliferation than by bone marrow mobilization. J Mol Cell Cardiol. 2013;57:32–42. doi: 10.1016/j.yjmcc.2012.12.018.
    1. Rossi F, Bertone C, Montanile F, Miglietta F, Lubrano C, Gandini L, Santiemma V. HDL cholesterol is a strong determinant of endothelial progenitor cells in hypercholesterolemic subjects. Microvasc Res. 2010;80:274–279. doi: 10.1016/j.mvr.2010.05.003.
    1. Masana L. Pitavastatin in cardiometabolic disease: therapeutic profile. Cardiovasc Diabetol. 2013;12:S2. doi: 10.1186/1475-2840-12-S1-S2.
    1. Yoshida O, Kondo T, Kureishi-Bando Y, Sugiura T, Maeda K, Okumura K, Muroara T. Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. Circ J. 2010;74:195–202. doi: 10.1253/circj.CJ-09-0345.
    1. Zhang YL, Hu J, Zhang ZX, Zeng DY, Qi GX. Pitavastatin enhances angiogenesis and perfusion in a murine mode of limb ischemia. Zhonghua Xin Xue Guan Bing Za Zhi. 2006;22:252–256.
    1. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, Silver M, Li T, Isner JM, Asahara T. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation. 2002;105:732–738. doi: 10.1161/hc0602.103673.
    1. Dworacka M, Krzyżagórska E, Wesołowska A, Borowska M, Iskakova S, Dworacki G. Statins in low doses reduce VEGF and bFGF serum levels in patients with type 2 diabetes mellitus. Pharmacology. 2014;93:32–38. doi: 10.1159/000357476.
    1. Sata M, Nishimatsu H, Suzuki E, Sugiura S, Yoshizumi M, Ouchi Y, Hirata Y, Nagai R. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J. 2001;15:2530–2532.
    1. Sata M, Nishimatsu H, Osuga JI, Tanaka K, Ishizaka N, Ishibashi S, Hirata Y, Nagai R. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension. 2004;43:1214–1220. doi: 10.1161/01.hyp.0000126186.29571.41.
    1. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110:624–637. doi: 10.1161/CIRCRESAHA.111.243386.
    1. Asahara T, Kawamoto A, Masuda H. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells. 2011;29:1650–1655. doi: 10.1002/stem.745.
    1. Gehling UM, Ergün S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schäfer B, Hossfeld DK, Fiedler W. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000;95:3106–3112.
    1. Madeddu P, Emanueli C, Pelosi E, Salis MB, Cerio AM, Bonanno G, Patti M, Stassi G, Condorelli G, Peschle C. Transplantation of low dose CD34 + KDR + cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J. 2004;18:1737–1739.
    1. Schmidt-Lucke C, Fichtlscherer S, Aicher A, Tschöpe C, Schultheiss HP, Zeiher AM, Dimmeler S. Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol. PLoS One. 2010;5:e13790. doi: 10.1371/journal.pone.0013790.
    1. Chen CH, Cheng BC, Leu S, Sun CK, Chua S, Yen CH, Kung CT, Chen YT, Chang LT, Yip HK. Circulating level of endothelial progenitor cells in healthy Taiwanese. Acta Cardiol Sin. 2010;26:94–101.
    1. Chiang CH, Leu HB, Huang PH, Chung FP, Huang CC, Wu TC, Chen JW, Lin SJ. SYNTAX score is associated with circulating endothelial progenitor cells in patients with coronary artery disease. Acta Cardiol Sin. 2012;28:216–224.
    1. Nishiyama Y, Ueda M, Otsuka T, Katsura K, Abe A, Nagayama H, Katayama Y. Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients. J Atheroscler Thromb. 2011;18:131–137. doi: 10.5551/jat.5553.
    1. Valkonen VP, Laakso J, Päivä H, Lehtimäki T, Lakka TA, Isomustajärvi M, Ruokonen I, Salonen JT, Laaksonen R. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events: does statin treatment influence plasma ADMA levels? Atheroscler Suppl. 2003;4:19–22. doi: 10.1016/S1567-5688(03)00029-1.
    1. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA) Vasc Med. 2005;10(Suppl 1):S49–S57. doi: 10.1177/1358836X0501000108.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel